Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTX 
BioNTech SE (BNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BNTX (1-star) is a SELL. SELL since 2 days. Profits (-7.32%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $137.11
1 Year Target Price $137.11
| 13 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.93% | Avg. Invested days 34 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.50B USD | Price to earnings Ratio - | 1Y Target Price 137.11 |
Price to earnings Ratio - | 1Y Target Price 137.11 | ||
Volume (30-day avg) 21 | Beta 1.24 | 52 Weeks Range 81.20 - 131.49 | Updated Date 08/28/2025 |
52 Weeks Range 81.20 - 131.49 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -1.41 | Actual -1.6 |
Profitability
Profit Margin -11.98% | Operating Margin (TTM) -167.45% |
Management Effectiveness
Return on Assets (TTM) -2.14% | Return on Equity (TTM) -1.84% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 8741038755 | Price to Sales(TTM) 8.51 |
Enterprise Value 8741038755 | Price to Sales(TTM) 8.51 | ||
Enterprise Value to Revenue 2.61 | Enterprise Value to EBITDA 110.81 | Shares Outstanding 240399008 | Shares Floating 93813198 |
Shares Outstanding 240399008 | Shares Floating 93813198 | ||
Percent Insiders 62.69 | Percent Institutions 23.08 |
Upturn AI SWOT
BioNTech SE
Company Overview
History and Background
BioNTech SE was founded in 2008 in Mainz, Germany, by Uu011fur u015eahin and u00d6zlem Tu00fcreci. Initially focused on cancer immunotherapy, the company gained global recognition for its rapid development of a COVID-19 vaccine in collaboration with Pfizer.
Core Business Areas
- mRNA Therapeutics: Development of mRNA-based therapies for cancer, infectious diseases, and other conditions. This includes individualized cancer vaccines and treatments for rare diseases.
- Cellular Therapies: Research and development of cell-based immunotherapies, including CAR-T cell therapies for cancer treatment.
- Protein Therapeutics: Development of protein-based therapeutics and antibodies for various diseases.
Leadership and Structure
The company is led by CEO and co-founder Uu011fur u015eahin. The organizational structure includes various departments focused on research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): Developed in collaboration with Pfizer, Comirnaty is an mRNA-based vaccine used to prevent COVID-19. It holds a significant market share in the global COVID-19 vaccine market, initially estimated around 70% in key markets but now significantly reduced due to waning demand and new vaccine technologies. Competitors include Moderna (mRNA), AstraZeneca (viral vector), and Novavax (protein subunit).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant market competition. The rise of mRNA technology has opened new avenues for vaccine development and personalized medicine.
Positioning
BioNTech SE is a leader in mRNA-based therapeutics, particularly in the field of vaccines. Its partnership with Pfizer provides a strong competitive advantage. They are diversifying into cancer therapies to offset the fall in Covid-19 vaccine revenue.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach hundreds of billions USD over the next decade. BioNTech is positioned to capture a significant share, diversifying from solely COVID-19 to various therapeutic areas including cancer and infectious diseases.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology platform
- Successful development and commercialization of COVID-19 vaccine
- Strategic partnership with Pfizer
- Strong research and development capabilities
- Experience in manufacturing at scale.
Weaknesses
- Reliance on a single product (COVID-19 vaccine)
- Dependence on partner Pfizer for commercialization
- Unproven success in therapeutic areas beyond vaccines
- Cash flow is highly cyclical as tied to the market demand for COVID-19 products.
Opportunities
- Expansion into new therapeutic areas (e.g., cancer immunotherapy)
- Development of new mRNA-based vaccines
- Strategic partnerships with other pharmaceutical companies
- Expansion into new geographic markets.
Threats
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Patent disputes and intellectual property challenges
- Declining demand for COVID-19 vaccines
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- MRNA
- NVAX
- PFE
Competitive Landscape
BioNTech has a strong mRNA technology platform, but faces competition from other established pharmaceutical companies and biotech firms. Its advantage lies in its partnership with Pfizer and its innovative pipeline. Competitors have diverse product portfolios or specialize in other technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by rapid expansion during the pandemic, driven by the success of the COVID-19 vaccine.
Future Projections: Future growth is projected to be dependent on the success of its pipeline of cancer therapies and other mRNA-based products. Analysts expect moderate growth in the long term as the company diversifies its product portfolio.
Recent Initiatives: Recent initiatives include expanding clinical trials for cancer therapies, forging new partnerships for drug development, and investing in manufacturing capacity.
Summary
BioNTech SE demonstrated exceptional innovation by quickly developing a COVID-19 vaccine but it is reliant on revenues from sales of that vaccine. The future is uncertain as COVID-19 vaccine demand decreases and new therapies will need to make up for this. The company is actively working to develop treatments for various diseases, especially cancer. Its partnership with Pfizer remains a key asset, but successfully broadening its product portfolio is crucial for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNTech SE
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6772 | Website https://www.biontech.de |
Full time employees 6772 | Website https://www.biontech.de | ||
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.